|
1
|
Miebach L, Berner J, Bekeschus S. In ovo model in cancer research and tumor immunology. Front Immunol 2022; 13:1006064. [PMID: 36248802 PMCID: PMC9556724 DOI: 10.3389/fimmu.2022.1006064] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2022] [Accepted: 09/13/2022] [Indexed: 11/15/2022] Open
Abstract
Considering cancer not only as malignant cells on their own but as a complex disease in which tumor cells interact and communicate with their microenvironment has motivated the establishment of clinically relevant 3D models in past years. Technological advances gave rise to novel bioengineered models, improved organoid systems, and microfabrication approaches, increasing scientific importance in preclinical research. Notwithstanding, mammalian in vivo models remain closest to mimic the patient’s situation but are limited by cost, time, and ethical constraints. Herein, the in ovo model bridges the gap as an advanced model for basic and translational cancer research without the need for ethical approval. With the avian embryo being a naturally immunodeficient host, tumor cells and primary tissues can be engrafted on the vascularized chorioallantoic membrane (CAM) with high efficiencies regardless of species-specific restrictions. The extraembryonic membranes are connected to the embryo through a continuous circulatory system, readily accessible for manipulation or longitudinal monitoring of tumor growth, metastasis, angiogenesis, and matrix remodeling. However, its applicability in immunoncological research is largely underexplored. Dual engrafting of malignant and immune cells could provide a platform to study tumor-immune cell interactions in a complex, heterogenic and dynamic microenvironment with high reproducibility. With some caveats to keep in mind, versatile methods for in and ex ovo monitoring of cellular and molecular dynamics already established in ovo are applicable alike. In this view, the present review aims to emphasize and discuss opportunities and limitations of the chicken embryo model for pre-clinical research in cancer and cancer immunology.
Collapse
Affiliation(s)
- Lea Miebach
- ZIK plasmatis, Leibniz Institute for Plasma Science and Technology (INP), Greifswald, Germany
- Department of General, Thoracic, Vascular, and Visceral Surgery, Greifswald University Medical Center, Greifswald, Germany
| | - Julia Berner
- ZIK plasmatis, Leibniz Institute for Plasma Science and Technology (INP), Greifswald, Germany
- Department of General, Thoracic, Vascular, and Visceral Surgery, Greifswald University Medical Center, Greifswald, Germany
- Department of Oral and Maxillofacial Surgery, Plastic Surgery, Greifswald University Medical Center, Greifswald, Germany
| | - Sander Bekeschus
- ZIK plasmatis, Leibniz Institute for Plasma Science and Technology (INP), Greifswald, Germany
- Department of General, Thoracic, Vascular, and Visceral Surgery, Greifswald University Medical Center, Greifswald, Germany
- *Correspondence: Sander Bekeschus,
| |
Collapse
|
|
2
|
Bichlmayer EM, Mahl L, Hesse L, Pion E, Haller V, Moehwald A, Hackl C, Werner JM, Schlitt HJ, Schwarz S, Kainz P, Brochhausen C, Groeger C, Steger F, Kölbl O, Daniel C, Amann K, Kraus A, Buchholz B, Aung T, Haerteis S. A 3D In Vivo Model for Studying Human Renal Cystic Tissue and Mouse Kidney Slices. Cells 2022; 11:cells11152269. [PMID: 35892566 PMCID: PMC9330914 DOI: 10.3390/cells11152269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Revised: 07/14/2022] [Accepted: 07/19/2022] [Indexed: 11/23/2022] Open
Abstract
(1) Background: Autosomal dominant polycystic kidney disease (ADPKD) is a frequent monogenic disorder that leads to progressive renal cyst growth and renal failure. Strategies to inhibit cyst growth in non-human cyst models have often failed in clinical trials. There is a significant need for models that enable studies of human cyst growth and drug trials. (2) Methods: Renal tissue from ADPKD patients who received a nephrectomy as well as adult mouse kidney slices were cultured on a chorioallantoic membrane (CAM) for one week. The cyst volume was monitored by microscopic and CT-based applications. The weight and angiogenesis were quantified. Morphometric and histological analyses were performed after the removal of the tissues from the CAM. (3) Results: The mouse and human renal tissue mostly remained vital for about one week on the CAM. The growth of cystic tissue was evaluated using microscopic and CT-based volume measurements, which correlated with weight and an increase in angiogenesis, and was accompanied by cyst cell proliferation. (4) Conclusions: The CAM model might bridge the gap between animal studies and clinical trials of human cyst growth, and provide a drug-testing platform for the inhibition of cyst enlargement. Real-time analyses of mouse kidney tissue may provide insights into renal physiology and reduce the need for animal experiments.
Collapse
Affiliation(s)
- Eva-Marie Bichlmayer
- Institute for Molecular and Cellular Anatomy, University of Regensburg, 93053 Regensburg, Germany; (E.-M.B.); (L.M.); (L.H.); (E.P.); (V.H.); (A.M.); (T.A.)
| | - Lina Mahl
- Institute for Molecular and Cellular Anatomy, University of Regensburg, 93053 Regensburg, Germany; (E.-M.B.); (L.M.); (L.H.); (E.P.); (V.H.); (A.M.); (T.A.)
| | - Leo Hesse
- Institute for Molecular and Cellular Anatomy, University of Regensburg, 93053 Regensburg, Germany; (E.-M.B.); (L.M.); (L.H.); (E.P.); (V.H.); (A.M.); (T.A.)
| | - Eric Pion
- Institute for Molecular and Cellular Anatomy, University of Regensburg, 93053 Regensburg, Germany; (E.-M.B.); (L.M.); (L.H.); (E.P.); (V.H.); (A.M.); (T.A.)
| | - Victoria Haller
- Institute for Molecular and Cellular Anatomy, University of Regensburg, 93053 Regensburg, Germany; (E.-M.B.); (L.M.); (L.H.); (E.P.); (V.H.); (A.M.); (T.A.)
| | - Andreas Moehwald
- Institute for Molecular and Cellular Anatomy, University of Regensburg, 93053 Regensburg, Germany; (E.-M.B.); (L.M.); (L.H.); (E.P.); (V.H.); (A.M.); (T.A.)
| | - Christina Hackl
- Department of Surgery, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany; (C.H.); (J.M.W.); (H.J.S.)
| | - Jens M. Werner
- Department of Surgery, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany; (C.H.); (J.M.W.); (H.J.S.)
| | - Hans J. Schlitt
- Department of Surgery, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany; (C.H.); (J.M.W.); (H.J.S.)
| | | | - Philipp Kainz
- KML Vision GmbH, A-8020 Graz, Austria; (S.S.); (P.K.)
| | | | - Christian Groeger
- Department for Radiotherapy, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany; (C.G.); (F.S.); (O.K.)
| | - Felix Steger
- Department for Radiotherapy, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany; (C.G.); (F.S.); (O.K.)
| | - Oliver Kölbl
- Department for Radiotherapy, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany; (C.G.); (F.S.); (O.K.)
| | - Christoph Daniel
- Department of Nephropathology, Friedrich-Alexander University Erlangen-Nürnberg, 91054 Erlangen, Germany; (C.D.); (K.A.)
| | - Kerstin Amann
- Department of Nephropathology, Friedrich-Alexander University Erlangen-Nürnberg, 91054 Erlangen, Germany; (C.D.); (K.A.)
| | - Andre Kraus
- Department of Nephrology and Hypertension, University Hospital Erlangen, University of Erlangen-Nuremberg, 91054 Erlangen, Germany; (A.K.); (B.B.)
| | - Björn Buchholz
- Department of Nephrology and Hypertension, University Hospital Erlangen, University of Erlangen-Nuremberg, 91054 Erlangen, Germany; (A.K.); (B.B.)
| | - Thiha Aung
- Institute for Molecular and Cellular Anatomy, University of Regensburg, 93053 Regensburg, Germany; (E.-M.B.); (L.M.); (L.H.); (E.P.); (V.H.); (A.M.); (T.A.)
- Faculty of Applied Healthcare Science, Deggendorf Institute of Technology, 94469 Deggendorf, Germany
| | - Silke Haerteis
- Institute for Molecular and Cellular Anatomy, University of Regensburg, 93053 Regensburg, Germany; (E.-M.B.); (L.M.); (L.H.); (E.P.); (V.H.); (A.M.); (T.A.)
- Correspondence:
| |
Collapse
|